<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2681224-A1" country="EP" doc-number="2681224" kind="A1" date="20140108" family-id="43838164" file-reference-id="318301" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146587042" ucid="EP-2681224-A1"><document-id><country>EP</country><doc-number>2681224</doc-number><kind>A1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12706836-A" is-representative="NO"><document-id mxw-id="PAPP154849234" load-source="docdb" format="epo"><country>EP</country><doc-number>12706836</doc-number><kind>A</kind><date>20120301</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220440252" load-source="docdb" format="original"><country>EP</country><doc-number>12706836.9</doc-number><date>20120301</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140550516" ucid="EP-11156792-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>11156792</doc-number><kind>A</kind><date>20110303</date></document-id></priority-claim><priority-claim mxw-id="PPC140555581" ucid="EP-12706836-A" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>12706836</doc-number><kind>A</kind><date>20120301</date></document-id></priority-claim><priority-claim mxw-id="PPC140550861" ucid="EP-2012053483-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>2012053483</doc-number><kind>W</kind><date>20120301</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989316959" load-source="docdb">C07D 501/12        20060101AFI20120921BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989621344" load-source="docdb" scheme="CPC">C07D 501/12        20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365759" lang="DE" load-source="patent-office">ABBAU VON PENICILLINVERBINDUNGEN</invention-title><invention-title mxw-id="PT132365760" lang="EN" load-source="patent-office">DEGRADATION OF PENICILLIN COMPOUNDS</invention-title><invention-title mxw-id="PT132365761" lang="FR" load-source="patent-office">DÉGRADATION DE COMPOSÉS DE PÉNICILLINE</invention-title><citations><non-patent-citations><nplcit><text>See references of WO 2012117038A1</text><sources><source mxw-id="PNPL67456279" load-source="docdb" name="SEA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919507280" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DSM SINOCHEM PHARM NL BV</last-name><address><country>NL</country></address></addressbook></applicant><applicant mxw-id="PPAR919510073" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.</last-name></addressbook></applicant><applicant mxw-id="PPAR919013676" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>DSM Sinochem Pharmaceuticals Netherlands B.V.</last-name><iid>101286702</iid><address><street>Alexander Fleminglaan 1</street><city>2613 AX Delft</city><country>NL</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919518140" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DEKKERS ROCUS MARINUS</last-name><address><country>NL</country></address></addressbook></inventor><inventor mxw-id="PPAR919540167" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DEKKERS, ROCUS, MARINUS</last-name></addressbook></inventor><inventor mxw-id="PPAR919013632" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>DEKKERS, ROCUS, MARINUS</last-name><address><street>P.O.Box 130</street><city>NL-6100 AC Echt</city><country>NL</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919019090" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>De Vroom, Erik</last-name><iid>101227016</iid><address><street>DSM Intellectual Property P.O. Box 4</street><city>6100 AA Echt</city><country>NL</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="EP-2012053483-W"><document-id><country>EP</country><doc-number>2012053483</doc-number><kind>W</kind><date>20120301</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012117038-A1"><document-id><country>WO</country><doc-number>2012117038</doc-number><kind>A1</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549848840" load-source="docdb">AL</country><country mxw-id="DS549768138" load-source="docdb">AT</country><country mxw-id="DS549767799" load-source="docdb">BE</country><country mxw-id="DS549850175" load-source="docdb">BG</country><country mxw-id="DS549864433" load-source="docdb">CH</country><country mxw-id="DS549767800" load-source="docdb">CY</country><country mxw-id="DS549768139" load-source="docdb">CZ</country><country mxw-id="DS549848841" load-source="docdb">DE</country><country mxw-id="DS549767805" load-source="docdb">DK</country><country mxw-id="DS549767806" load-source="docdb">EE</country><country mxw-id="DS549850124" load-source="docdb">ES</country><country mxw-id="DS549850176" load-source="docdb">FI</country><country mxw-id="DS549864442" load-source="docdb">FR</country><country mxw-id="DS549848846" load-source="docdb">GB</country><country mxw-id="DS549767807" load-source="docdb">GR</country><country mxw-id="DS549848847" load-source="docdb">HR</country><country mxw-id="DS549768140" load-source="docdb">HU</country><country mxw-id="DS549864443" load-source="docdb">IE</country><country mxw-id="DS549767808" load-source="docdb">IS</country><country mxw-id="DS549850177" load-source="docdb">IT</country><country mxw-id="DS549767821" load-source="docdb">LI</country><country mxw-id="DS549850186" load-source="docdb">LT</country><country mxw-id="DS549780636" load-source="docdb">LU</country><country mxw-id="DS549850187" load-source="docdb">LV</country><country mxw-id="DS549850188" load-source="docdb">MC</country><country mxw-id="DS549780645" load-source="docdb">MK</country><country mxw-id="DS549780646" load-source="docdb">MT</country><country mxw-id="DS549850125" load-source="docdb">NL</country><country mxw-id="DS549917757" load-source="docdb">NO</country><country mxw-id="DS549850130" load-source="docdb">PL</country><country mxw-id="DS549780647" load-source="docdb">PT</country><country mxw-id="DS549864444" load-source="docdb">RO</country><country mxw-id="DS549780648" load-source="docdb">RS</country><country mxw-id="DS549850131" load-source="docdb">SE</country><country mxw-id="DS549768149" load-source="docdb">SI</country><country mxw-id="DS549917758" load-source="docdb">SK</country><country mxw-id="DS549917759" load-source="docdb">SM</country><country mxw-id="DS549850189" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99836178" ref-ucid="WO-2012117038-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates to the degradation of β-lactam compounds such as penicillins in the presence of other β-lactam compounds such as cephalosporins. Furthermore the present invention relates to the use of sulfite in the degradation of penicillins, for example in industrial waste streams.</p></abstract><abstract mxw-id="PA100331950" ref-ucid="WO-2012117038-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates to the degradation of ß-lactam compounds such as penicillins in the presence of other ß-lactam compounds such as cephalosporins. Furthermore the present invention relates to the use of sulfite in the degradation of penicillins, for example in industrial waste streams.</p></abstract><abstract mxw-id="PA99836179" ref-ucid="WO-2012117038-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne la dégradation de composés β-lactames, tels que des pénicillines, en présence d'autres composés β-lactames, tels que les céphalosporines. La présente invention concerne en outre l'utilisation de sulfite dans la dégradation de pénicillines, par exemple dans des flux de déchets industriels.</p></abstract><abstract mxw-id="PA100331951" ref-ucid="WO-2012117038-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne la dégradation de composés ß-lactames, tels que des pénicillines, en présence d'autres composés ß-lactames, tels que les céphalosporines. La présente invention concerne en outre l'utilisation de sulfite dans la dégradation de pénicillines, par exemple dans des flux de déchets industriels.</p></abstract><description mxw-id="PDES51233194" ref-ucid="WO-2012117038-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> DEGRADATION OF PENICILLIN COMPOUNDS </p><p id="p0002" num="0002">Field of the invention </p><p id="p0003" num="0003">The present invention relates to the degradation of β-lactam compounds such as penicillins in the presence of other β-lactam compounds such as cephalosporins. Furthermore the present invention relates to the use of sulfite in the degradation of penicillins, for example in industrial waste streams. </p><p id="p0004" num="0004">Background of the invention β-Lactam antibiotics are advantageously used already for several decades in order to cure mankind from all kinds of infectious diseases. Nevertheless, under certain circumstance, β-lactams can be harmful and there are strict requirements on the absence of β-lactams in certain products, such as food products, waste, but also certain drugs and even antibiotic products themselves. For instance, β-lactam antibiotics of the cephalosporin type preferably do not contain β-lactam antibiotics of the penicillin type and vice versa. The Pharmacopeia contains requirements of the purity of cephalosporins with respect to penicillins. </p><p id="p0005" num="0005"> 7-Aminodesacetoxycephalosporanic acid (7-ADCA) is the starting material for cephalosporin type β-lactam antibiotics such as cephalexin, cefadroxil and cephradine. The traditional route to 7-ADCA starts with penicillin G and thereby has an inherent risk that residual penicillin compounds such as penicillin G and 6-aminopenicillanic acid (6-APA) will be present in 7-ADCA. Novel production of 7-ADCA via fermentation techniques using a Penicillium strain transformed with an expandase gene as disclosed in WO 93/05158, WO 95/04148, WO 95/04149, WO 98/48036, WO 98/48034, and/or WO 98/48035 inherently have, at various stages in the process, contaminating levels of penicillin-compounds such as 6-APA. There is therefore a need for methods to selectively degrade β-lactam compounds, for instance to selectively degrade 6-APA. 
<!-- EPO <DP n="3"/>-->
 Detailed description of the invention </p><p id="p0006" num="0006">In general, β-lactams are unstable compounds and there exist several methods to degrade β-lactams. However, the existing methods use either harsh reaction conditions and/or lack selectivity and/or are expensive and/or laborious. For instance, 6-APA may be degraded selectively by incubation at selected temperature- and pH- ranges or in the presence of C0<sub>2</sub> and other sources of C0<sub>2</sub>. Also, β-lactamases can be used for selective degradation. The inactivation of A<sup>2</sup>-pentenylpenicillin and penicillin G using sodium bisulfite has been reported by Florey et al. ("Antibiotics", Volume II (1949) Oxford University Press, London, 802) and by Clarke et al. ("The Chemistry of Penicillin" (1949) Princeton University Press, Princeton, 207-242) although these studies do not suggest any selectivity related with sodium bisulfite. Finally, several purification methods are known that separate 6-APA or other penicillins from cephalosporin products. </p><p id="p0007" num="0007">In a first aspect, it has surprisingly been found that a selective degradation of penicillin compounds can be obtained by carrying out the degradation in the presence of sulfite. Thus, the invention provides a process for the degradation of a penicillin compound of general formula (1) in a mixture comprising said compound of general formula (1) and a cephalosporin compound of general formula (2). </p><p id="p0008" num="0008"><img id="imgf000003_0001" he="35" wi="99" file="imgf000003_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/></p><p id="p0009" num="0009"> (1) (2) </p><p id="p0010" num="0010">In the compounds of general formula (1) and (2) F^ and R<sub>2</sub> are hydrogen or acyl groups s u ch as , fo r exa m p l e , ad i py l , 2-aminoadipyl, 2-amino-4-thiazolylacetyl, 2-amino-4-thiazolyl(methoxyimino)acetyl, 2,5-dihydrophenylglycyl, 2-furanyl(methoxy- imino)acetyl, glutaryl, hydroxyphenylacetyl, 4-hydroxyphenylglycyl, phenoxyacetyl, phenylacetyl, phenylglycyl, 4-pyridinylthioacetyl, 1 /-/-tetrazol-1-ylacetyl or 
<!-- EPO <DP n="4"/>-->
 2-thienylacetyl. The aforementioned groups are widely present in the majority of β-lactams with therapeutic use. For similar purposes, the group R<sub>3</sub> in the compound of general formula (2) can be hydrogen or a moiety such as acetamidomethyl, acetoxymethyl, chlorine, ethenyl, hydrogen, hydroxymethyl, methoxy, methoxymethyl, methyl, methylpyridinium, (1-methyl-1 /-/-tetrazol-5-ylth io) m ethyl , propenyl , 1 ,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1 ,2,4-triazin-3-ylthio)methyl or (1 ,3,4-thiadiazol-2- ylthio)methyl. Examples of compounds of general formula (2) from which penicillin compounds may be removed according to the present invention are 7-aminocephalosporanic acid (7-ACA), 7-ADCA, adipyl-7-ADCA, cefaclor, cefadroxil, cefamandole, cefatrizine, cefazedone, cefazolin, cefdinir, cefixime, cefmenoxime, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotiam, cefpimizole, cefpiramide, cefprozil, cefpodoxime, cefroxadine, cefsulodin, ceftazidime, cefteram, ceftezole, ceftibuten, ceftizoxime, ceftriaxone, cefuroxime, cefuzonam, cephalexin, cephaloglycin, cephaloridine, cephalosporin C, cephalothin, cephapirin and cephradine. </p><p id="p0011" num="0011"> In one embodiment, the penicillin compound of general formula (1) preferably is selected from the group consisting of 6-APA and any 6-N-acyl derivative such adipyl-6-APA, penicillin G, penicillin V, amoxicillin, ampicillin or those disclosed in the prior art cited above. In a preferred embodiment, the penicillin compound of general formula (1) is 6-APA or adipyl-6-APA. In another preferred embodiment the cephalosporin compound of general formula (2) is 7-ADCA or any 7-N-acyl derivative of 7-ADCA such as adipyl-7-ADCA. Most preferred is degradation of 6-APA and/or adipyl-6-APA in a mixture comprising 7-ADCA and/or adipyl-7-ADCA. </p><p id="p0012" num="0012"> The process may be carried out at any suitable temperature, such as a temperature between 0 and 60°C, preferably between 10 and 40°C. The skilled person is very well capable of selecting the appropriate temperature for the degradation of the penicillin compound in the process of the invention. </p><p id="p0013" num="0013"> In the context of the present invention the term "sulfite" (or "sulphite") refers to any compound comprising sulfur in oxidation state (also referred to as oxidation number or valency) 4<sup>+</sup>. Preferred examples are S0<sub>2</sub>, (HS0<sub>3</sub>)<sup>"</sup> and (S0<sub>3</sub>)<sup>2"</sup> which exist next to one another in aqueous solutions in ratio's depending on the pH. For example, at pH 1 an aqueous solution contains approximately 90% S0<sub>2</sub> and approximately 10% (HS0<sub>3</sub>)<sup>"</sup>, at pH 7 an aqueous solution contains approximately 50% (HS0<sub>3</sub>)<sup>"</sup> and approximately 50% (S0<sub>3</sub>)<sup>2"</sup> and at pH 8 an aqueous solution contains approximately 10% (HS0<sub>3</sub>)<sup>"</sup> and 
<!-- EPO <DP n="5"/>-->
 approximately 90% (S0<sub>3</sub>)<sup>2"</sup>. Sulfite may be added in any form. A suitable source is NaHS0<sub>3</sub> but other sources such as metal salts of (HS0<sub>3</sub>)<sup>"</sup> or (S0<sub>3</sub>)<sup>2"</sup> or (S<sub>2</sub>0<sub>3</sub>)<sup>2"</sup> (meta bisulfite) may be used as well. Also, gaseous S0<sub>2</sub> may be brought into the reaction mixture. The skilled person is very well capable of selecting the appropriate source of sulfite that can be used in the process of the invention. </p><p id="p0014" num="0014"> Preferably the process is carried out at a pH value between 3 and 9, more preferably between 4 and 8, more preferably between 5 and 7, most preferably between 5.5 and 6.5. Preferably the pH is such that at least 10% of sulfite is present as (HS0<sub>3</sub>)<sup>"</sup> which usually is between pH 1 and 8; more preferably the pH is such that at least 40% of sulfite is present as (HS0<sub>3</sub>)<sup>"</sup> which usually is between pH 1.6 and 7.2, most preferably the pH is such that at least 80% of sulfite is present as (HS0<sub>3</sub>)<sup>"</sup> which usually is between pH 2.5 and 6.3. </p><p id="p0015" num="0015"> In the context of the present invention, "degradation of a penicillin compound" is defined as that in the penicillin compound preferentially the 4-membered β-lactam-ring is cleaved, resulting in a degradation product of the penicillin compound. Preferably, the rate constant k<sub>(1)</sub> (in hr<sup>"1</sup>.(g/l)<sup>"1</sup>) representing degradation of the compound of general formula (1) is 10 times the rate constant k<sub>(2)</sub> (in hr<sup>"1</sup>.(g/l)<sup>"1</sup>) representing degradation of the compound of general formula (2). More preferably k<sub>(1)</sub> is 10 to 100 times the rate constant k<sub>(2)</sub> and most preferably k<sub>(1)</sub> is 50 to 1000 times the rate constant k<sub>(2)</sub>. </p><p id="p0016" num="0016">In another aspect, the invention provides the use of sulfite for the degradation of a penicillin compound, more preferably a penicillin compound selected from the group consisting of 6-APA and any 6-N-acyl derivative such adipyl-6-APA, penicillin G, penicillin V, amoxicillin, ampicillin or those disclosed in the prior art cited above. In one embodiment, the invention provides the use of sulfite for the degradation of a penicillin compound wherein the penicillin compound is selectively degraded in the presence of a cephalosporin compound. A preferred embodiment is th e u s e of sulfite for the degradation of a contaminating penicillin compound in a process for the production of a cephalosporin compound. In another embodiment, the invention provides the use of sulfite for the degradation of penicillin in a waste stream, such as a mycelium of a production organism used for the production of β-lactam antibiotic compounds such as penicillin producing microorganisms from the genus Penicillium. Said use has significant practical importance as traces of penicillins in waste streams are hazardous 
<!-- EPO <DP n="6"/>-->
 for the public health in view of unwanted and/or uncontrolled development of bacterial resistance against penicillins. </p><p id="p0017" num="0017">EXAMPLES </p><p id="p0018" num="0018">Materials and methods </p><p id="p0019" num="0019"> The concentration of 6-APA was determined by HPLC using a Dionex Ultimate 3000 RS equipped with a Lichrospher RP-18 column (5 μηι, 250*4.6 mm (Merck)) operated at a flow of 1.3 ml/min. Other conditions: </p><p id="p0020" num="0020"> • Eluens (isocratic): 6.62 g K<sub>2</sub>HP0<sub>4</sub> + 17.76 g KH<sub>2</sub>P0<sub>4</sub> are dissolved in purified water. </p><p id="p0021" num="0021"> 100 ml acetonitrile (HPLC grade) is added. The volume is adjusted to a total of 2 liter by addition of purified water </p><p id="p0022" num="0022"> • Run time 12 min </p><p id="p0023" num="0023"> • Injection volume 10 μΙ </p><p id="p0024" num="0024"> • Wavelength for detection: 214 nm </p><p id="p0025" num="0025"> • Temperature: 20-25 °C </p><p id="p0026" num="0026"> Under these conditions 6-APA eluted at 2.9 minutes and pHPG at 1.5 min. </p><p id="p0027" num="0027"> Sulfite was determined using the Reflectoquant sulfite test (Merck prod. nr.</p><p id="p0028" num="0028">1.16987.0001) measured on an RQflex 2 (Merck prod. nr. 1.16970.0001). </p><p id="p0029" num="0029">Example 1 </p><p id="p0030" num="0030"> Degradation of 6-APA by NaHS0<sub>3</sub> </p><p id="p0031" num="0031"> The degradation of 6-APA ((1), = H) was measured as a function of time, bisulfite concentration (0-8 g/l) and at several pH-values (4, 6 and 9). Solutions containing 1 g/l 6-APA in water were brought to the desired pH using 1 N NaOH and/or 1 N H<sub>2</sub>S0<sub>4</sub>. Then the indicated amounts of NaHS0<sub>3</sub> were added. The various mixtures were incubated at 20°C and samples were taken in time in order to measure the residual 6- APA concentration as well as remaining sulfite concentration. Sulfite can be present in the solution as H<sub>2</sub>S0<sub>3</sub>, HS0<sub>3</sub><sup>"</sup>, or S0<sub>3</sub><sup>2"</sup>, depending on the pH. H<sub>2</sub>S0<sub>3</sub> has two pKa values, one at -1.8 and a second at -7.0. At pH values 4 and 6, virtually all sulfite is present as HS0<sub>3</sub><sup>"</sup> while at pH 9 virtually all sulfite is present as S0<sub>3</sub><sup>2"</sup>. Tables 1 a-1 c show the time-dependent degradation of 6-APA by sulfite at pH 4, 6 and 9 respectively. 
<!-- EPO <DP n="7"/>-->
 Table 1 a: 6-APA degradation as a function of the sulfite concentration at pH=4 </p><p id="p0032" num="0032"><img id="imgf000007_0001" he="86" wi="87" file="imgf000007_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/><img id="imgf000007_0002" he="16" wi="107" file="imgf000007_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0033" num="0033">Table 1 b: 6-APA degradation as a function of the sulfite concentration at pH=6 </p><p id="p0034" num="0034"><img id="imgf000007_0003" he="86" wi="87" file="imgf000007_0003.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0035" num="0035"> k' 0.000 0.151 0.950 Average </p><p id="p0036" num="0036"> k 0.076 0.119 0.097 
<!-- EPO <DP n="8"/>-->
 Table 1 c: 6-APA degradation as a function of the sulfite concentration at pH=9 </p><p id="p0037" num="0037"><img id="imgf000008_0002" he="61" wi="87" file="imgf000008_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/><img id="imgf000008_0003" he="16" wi="107" file="imgf000008_0003.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0038" num="0038">The results show that the degradation rate depends on both the 6-APA concentration [6-APA] and the (bi)sulfite-concentration [S0<sub>3</sub><sup>2"</sup>] and is therefore at least second order. The reaction could be modeled using a second order rate equation: 
<img id="imgf000008_0001" he="6" wi="34" file="imgf000008_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/>
 in which k is the rate coefficient or rate constant (in hr <sup>1</sup>.(g/l)<sup>"1</sup>). </p><p id="p0039" num="0039"> The S0<sub>3</sub><sup>2"</sup>-concentrations measured during the reactions show that the concentration remains quite constant during the degradation (not shown). Sulfite was present in excess. Therefore the rate equation could be simplified to a pseudo first order rate equation: r = k'[6APA] in which k'= k[SO^] (in hr<sup>"1</sup>). </p><p id="p0040" num="0040"> At pH 4, 6 and 9 for each sulfite-concentration k' and subsequently k were calculated (see Tables 1 a-1 c). The fastest degradation rate of 6-APA is found at pH 6. From the calculated k-values it can be deduced that the degradation at pH 9 is approximately 30- 
<!-- EPO <DP n="9"/>-->
 fold slower compared to pH 6. At pH 4, the degradation rate is 2.5-fold lower, however still significant. </p><p id="p0041" num="0041">Example 2 </p><p id="p0042" num="0042"> Degradation of adipyl-7-ADCA by NaHS0<sub>3</sub> at pH 7 </p><p id="p0043" num="0043"> The degradation of adipyl-7-ADCA ((2), R<sub>2</sub> = adipyl, R<sub>3</sub> = CH<sub>3</sub>) was measured as a function of time, bisulfite concentration (0-12 g/l) and at pH=7. For experimental details and analysis see Example 1. </p><p id="p0044" num="0044">Table 2: Adipyl-7-ADCA degradation as a function of sulfite concentration at pH=7 </p><p id="p0045" num="0045"><img id="imgf000009_0001" he="59" wi="154" file="imgf000009_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0046" num="0046">The data in table 2 show that adipyl-7-ADCA is much more resistant against the degradation by sulfite. Hardly any degradation takes place. This is illustrated by comparing the second order rate constant for 6-APA at pH=6 (0.097) with the second order rate constant for adipyl-7-ADCA at pH=7 (0.00020) which shows that 6-APA is degraded 485 times faster than adipyl-7-ADCA. </p><p id="p0047" num="0047">Example 3 </p><p id="p0048" num="0048"> Degradation of 7-ADCA by different concentrations of NaHS0<sub>3</sub></p><p id="p0049" num="0049">The degradation of 7-ADCA ((2), R<sub>2</sub> = H, R<sub>3</sub> = CH<sub>3</sub>) was measured as a function of time at bisulfite concentrations of 0 g/l, 4 g/l, 13 g/l and 16 g/l. Four 7-ADCA solutions (50 ml) were stirred at 20°C for 2 days. Concentrations of 7-ADCA were measured by H PLC, accuracy ± 2%. The pH was adjusted to 7.6 with 1 M NaOH or to pH 9.4 as indicated in the below Table. 
<!-- EPO <DP n="10"/>-->
 Table 3: 7-ADCA degradation as a function of the sulfite concentration </p><p id="p0050" num="0050"> Sodium bisulfite (g/l) </p><p id="p0051" num="0051"> 0 13 16 4</p><p id="p0052" num="0052">Time </p><p id="p0053" num="0053"> pH 7.6 pH 7.6 pH 7.6 pH 9.4 (min) </p><p id="p0054" num="0054"> 7-ADCA 7-ADCA 7-ADCA 7-ADCA mM % mM % mM % mM %</p><p id="p0055" num="0055">0 102.06 100.0 96.62 100.0 113.40 100.0 126.17 100.0</p><p id="p0056" num="0056">30 92.33 95.6 </p><p id="p0057" num="0057"> 40 114.84 101 .3 </p><p id="p0058" num="0058"> 60 99.97 98.0 126.58 100.3</p><p id="p0059" num="0059">75 94.07 97.4 </p><p id="p0060" num="0060"> 90 113.65 100.2 </p><p id="p0061" num="0061"> 120 126.50 100.3</p><p id="p0062" num="0062">125 94.17 97.5 </p><p id="p0063" num="0063"> 130 100.55 98.5 </p><p id="p0064" num="0064"> 180 93.41 96.7 114.06 100.6 </p><p id="p0065" num="0065"> 200 123.11 97.6</p><p id="p0066" num="0066">225 99.61 97.6 </p><p id="p0067" num="0067"> 285 116.14 102.4 </p><p id="p0068" num="0068"> 300 124.97 99.1</p><p id="p0069" num="0069">310 93.43 96.7 </p><p id="p0070" num="0070"> 325 99.02 97.0 </p><p id="p0071" num="0071"> 1740 100.85 98.8 92.92 96.2 112.54 99.2 123.73 98.1</p><p id="p0072" num="0072">2880 100.26 98.2 91.25 94.4 110.75 97.7 122.64 97.2</p><p id="p0073" num="0073">2880 101.85 99.8 92.14 95.4 114.02 100.5 125.11 99.2 (dupl.) 
<!-- EPO <DP n="11"/>-->
</p><p id="p0074" num="0074">Example 4 </p><p id="p0075" num="0075"> Degradation of 7-ADCA by NaHS0<sub>3</sub> at pH 10 </p><p id="p0076" num="0076"> The degradation of 7-ADCA ((2), R<sub>2</sub> = H, R<sub>3</sub> = CH<sub>3</sub>) was measured as a function of time at a bisulfite concentration of 3 g/l and at pH=10. For experimental details and analysis see Example 1. </p><p id="p0077" num="0077">Table 4: 7-A DCA degradation as a fu nction of ti me at pH = 1 0 and a bisulfite concentration of 3 g/l. </p><p id="p0078" num="0078"><img id="imgf000011_0001" he="34" wi="42" file="imgf000011_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="no"/></p><p id="p0079" num="0079">Example 5 </p><p id="p0080" num="0080"> Degradation of 6-APA by NaHS0<sub>3</sub> in the presence of 7-ADCA and adipyl-7-ADCA</p><p id="p0081" num="0081">The pH of mixtures (500 ml) comprising 6-APA ((1), R-<sub>\</sub> = H), 7-ADCA ((2), R<sub>2</sub> = H, R<sub>3</sub> = CH<sub>3</sub>) and adipyl-7-ADCA ((2), R<sub>2</sub> = adipyl, R<sub>3</sub> = CH<sub>3</sub>) were adjusted using 4N NaOH and 6N H<sub>2</sub>S0<sub>4</sub> to 2.7 (Table 5a), 4.2 (Table 5b) and 6.0 (Table 5c). At t=0 a sample was taken of the obtained solutions (before bisulfite was added) . At 1 9±3°C, to each solution a solution of 25% sodium bisulfite was added with a flow of 30 ml/hr (60 ml.r<sup>1</sup>.hr<sup>"1</sup>). Samples (2 ml) were taken at t=5, 20, 40 and 60 minutes. Samples for 6- APA analysis were diluted twice in phosphate buffer pH 7.5 and analyzed by LC-MS. Samples for 7-ADCA and adipyl-7-ADCA analysis were directly diluted 151x and measured by HPLC. </p><p id="p0082" num="0082">Table 5a: Degradation as a function of time at pH=2.7. </p><p id="p0083" num="0083"> Time 6-APA Adipyl-7-ADCA 7-ADCA </p><p id="p0084" num="0084"> (min) mg % g % g % </p><p id="p0085" num="0085"> 0 1 1 .5 100 6.28 100 0.09 100</p><p id="p0086" num="0086">5 9.0 79 6.32 101 0.10 106</p><p id="p0087" num="0087">20 0.4 3 6.44 102 0.10 107</p><p id="p0088" num="0088">40 0.2 1 6.30 100 0.09 103</p><p id="p0089" num="0089">60 0.1 1 6.28 100 0.09 105 
<!-- EPO <DP n="12"/>-->
 Table 5b: Degradation as a function of time at pH=4.2. </p><p id="p0090" num="0090"><img id="imgf000012_0001" he="41" wi="157" file="imgf000012_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0091" num="0091">Table 5c: Degradation as a function of time at pH=6.0. </p><p id="p0092" num="0092"><img id="imgf000012_0002" he="47" wi="157" file="imgf000012_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes"/></p><p id="p0093" num="0093">Example 6 </p><p id="p0094" num="0094"> Degradation of adipyl-6-APA vs. adipyl-7-ADCA by NaHS0<sub>3</sub> at 46±2°C </p><p id="p0095" num="0095"> Adipyl-7-ADCA ((2), R<sub>2</sub> = adipyl, R<sub>3</sub> = CH<sub>3</sub>; 95% purity, 7.06 mg, ~1 equiv.) and adipyl-6-APA ((1), = adipyl; 44% purity, 14.65 mg, ~1 equiv.) were dissolved in 4 ml_ of phosphate buffer, pH=6-7. In order to obtain a clear solution, the sample was placed for 2-3 minutes in ultrasonic bath. 550μΙ was transferred to an NMR tube and placed into a spectrometer (700 MHz, preheated at 46±2°C). The sample was kept in the spectrometer and a spectrum was recorded at the times indicated in Table 6. </p><p id="p0096" num="0096"> In a next experiment, adipyl-7-ADCA ((2), R<sub>2</sub> = adipyl, R<sub>3</sub> = CH<sub>3</sub>; 95% purity, 6.66 mg, ~1 equiv.), adipyl-6-APA ((1), = adipyl; 44% purity, 14.57 mg, ~1 equiv.) and NaHS0<sub>3</sub> (9.43 mg, 4.7 equiv.) were dissolved in 4 ml_ of phosphate buffer, pH=6-7. In order to obtain a clear solution, the sample was placed for 2-3 minutes in ultrasonic bath. 550μΙ was transferred to an NMR tube and placed into a spectrometer (700 MHz, preheated at 46±2°C). The sample was kept in the spectrometer and a spectrum was recorded at the times indicated in Table 6. 
<!-- EPO <DP n="13"/>-->
 Decomposition of the title compounds was determined by measurement of the integral of the doublet at 5.4 ppm (β-lactam ring of adipyl-6-APA) and the doublet at 5.05 ppm (β-lactam ring of adipyl-7-ADCA). The initial increase of both adipyl-6-APA and adipyl-7-ADCA signals is probably a consequence of the measurement being taken before the sample has reached the desired temperature of 46±2°C. The results are depicted in Table 6 indicating that, in the presence of sulfite, adipyl-6-APA is degraded preferentially over adipyl-7-ADCA. </p><p id="p0097" num="0097">Table 6: Degradation of adipyl-6-APA vs. adipyl-7-ADCA by NaHS0<sub>3</sub> at 46±2°C and pH=6. </p><p id="p0098" num="0098"> Adipyl-6-APA Adipyl-7-ADCA </p><p id="p0099" num="0099"> Time </p><p id="p0100" num="0100"> (integral of doublet at 5.4 ppm) (integral of doublet at 5.05 ppm) (min) </p><p id="p0101" num="0101"> No NaHS0<sub>3</sub> NaHS0<sub>3</sub> No NaHS0<sub>3</sub> NaHS0<sub>3</sub> </p><p id="p0102" num="0102"> 2 5.89 5.40 5.27 4.64 </p><p id="p0103" num="0103"> 30 6.22 5.80 5.65 5.24 </p><p id="p0104" num="0104"> 45 6.23 5.78 5.67 5.26 </p><p id="p0105" num="0105"> 60 6.19 5.87 5.67 5.35 </p><p id="p0106" num="0106"> 75 6.13 5.70 5.61 5.33 </p><p id="p0107" num="0107"> 150 5.98 5.34 5.55 5.20 </p><p id="p0108" num="0108"> 265 5.70 5.03 5.46 5.25 </p><p id="p0109" num="0109"> 390 5.68 4.51 5.64 5.12 </p><p id="p0110" num="0110"> 540 5.49 4.09 5.63 5.08 </p><p id="p0111" num="0111"> 790 5.44 3.38 5.79 5.14 
</p></description><claims mxw-id="PCLM44852365" ref-ucid="WO-2012117038-A1" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="14"/>-->CLAIMS </claim-statement><claim id="clm-0001" num="1"><claim-text>A process for the degradation of a compound of general formula (1) in a mixture comprising said compound of general formula (1) and a compound of general formula 2) </claim-text><claim-text> <img id="imgf000014_0001" he="35" wi="98" file="imgf000014_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (1) (2) </claim-text><claim-text> wherein and R<sub>2</sub> are independently chosen from the list consisting of adipyl, 2-aminoadipyl, 2-amino-4-thiazolylacetyl, 2-amino-4-thiazolyl(methoxy- imino)acetyl, 2,5-dihydrophenylglycyl, 2-furanyl(methoxyimino)acetyl, glutaryl, hydrogen, hydroxyphenylacetyl, 4-hydroxyphenylglycyl, phenoxyacetyl, phenylacetyl, phenylglycyl, 4-pyridinylthioacetyl, 1 /-/-tetrazol-1-ylacetyl and 2-thienylacetyl a n d wh ere i n R<sub>3</sub> is chosen from the list consisting of acetamidomethyl, acetoxymethyl, chlorine, ethenyl, hydrogen, hydroxymethyl, methoxy, methoxymethyl, methyl, methylpyridinium, (1-methyl-1 /-/-tetrazol-5- ylthio)methyl, propenyl, 1 ,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1 ,</claim-text></claim><claim id="clm-0002" num="2"><claim-text>2,4-triazin-3- ylthio)methyl and (1 ,</claim-text></claim><claim id="clm-0003" num="3"><claim-text>3,</claim-text></claim><claim id="clm-0004" num="4"><claim-text>4-thiadiazol-2-ylthio)methyl, characterized in that said degradation is carried out in the presence of sulfite. </claim-text><claim-text>Process according to claim 1 wherein is the same as R<sub>2</sub>. </claim-text><claim-text>Process according to claim 1 wherein is hydrogen and R<sub>2</sub> is adipyl. </claim-text><claim-text>Process according to any one of claims 1 to 3 wherein R<sub>3</sub> is methyl. </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. Process according to any one of claims 1 to 4 wherein said sulfite is a bisulfite. </claim-text></claim><claim id="clm-0006" num="6"><claim-text><!-- EPO <DP n="15"/>--> Process according to any one of claims 1 to 5 wherein said degradation is carried out at a pH between 3 and 9. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>Process according to any one of claims 1 to 6 wherein the rate coefficient k<sub>(1)</sub> for degradation of said compound of general formula (1) is at least 10 times the rate coefficient k<sub>(2)</sub> for degradation of said compound of general formula (2). </claim-text></claim><claim id="clm-0008" num="8"><claim-text>Use of sulfite for the degradation of a compound of formula (1) in an aqueous mixture comprising said compound of general formula (1) and a compound of general for </claim-text><claim-text> <img id="imgf000015_0001" he="43" wi="99" file="imgf000015_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no"/> </claim-text><claim-text> (1) (2) </claim-text><claim-text> wherein and R<sub>2</sub> are independently chosen from the list consisting of adipyl, 2-a m i n o a d i p y 1 , 2-amino-4-thiazolylacetyl, 2-amino-4-thiazolyl(methoxy- imino)acetyl, 2,5-dihydrophenylglycyl, 2-furanyl(methoxyimino)acetyl, glutaryl, hydrogen, hydroxyphenylacetyl, 4-hydroxyphenylglycyl, phenoxyacetyl, phenylacetyl, phenylglycyl, 4-pyridinylthioacetyl, 1 /-/-tetrazol-1-ylacetyl and 2-thienylacetyl and wherein R<sub>3</sub> is chosen from the list consisting of acetamidomethyl, acetoxymethyl, chlorine, ethenyl, hydrogen, hydroxymethyl, methoxy, methoxymethyl, methyl, methylpyridinium, (1-methyl-1 /-/-tetrazol-5- ylthio)methyl, propenyl, 1 ,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1 ,2,4-triazin-3- ylthio)methyl and (1 ,3,4-thiadiazol-2-ylthio)methyl. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. Use according to claim 8 wherein said aqueous mixture is a waste stream. </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
